Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    ILEVRO

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 33,026Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Harrow To Present Three Abstracts At ASCRS 2026 Meeting
    Harrow To Present Three Abstracts At ASCRS 2026 Meeting

    18 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/18/3258016/0/en/Harrow-Announces-Three-Abstracts-Accepted-for-Presentation-at-ASCRS-2026-Annual-Meeting.html

    GLOBENEWSWIRE
    18 Mar 2026
    Share Share
    Harrow Closes Acquisition of U.S. Rights to ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE
    Harrow Closes Acquisition of U.S. Rights to ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE

    23 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230123005117/en

    BUSINESSWIRE
    23 Jan 2023
    Share Share
    Novartis, busy with its restructuring, sells 5 eye drugs for up to $175M
    Novartis, busy with its restructuring, sells 5 eye drugs for up to $175M

    15 Dec 2022

    // Zoey Becker FIERCEPHARMA

    https://www.fiercepharma.com/pharma/novartis-isnt-done-shaking-things-sells-five-eyecare-drugs-harrow-130-million

    Zoey Becker FIERCEPHARMA
    15 Dec 2022
    Share Share
    Imprimis NJOF, LLC Receives FDA Warning Letter
    Imprimis NJOF, LLC Receives FDA Warning Letter

    09 Jul 2019

    // FDA

    https://www.pharmacompass.com/pdf/news/imprimis-njof-llc-receives-fda-warning-letter-1562735073.pdf

    FDA
    09 Jul 2019
    Share Share
    Mati Therapeutics PhII Nepafenac Evolute® Trial Results Show Significant Post
    Mati Therapeutics PhII Nepafenac Evolute® Trial Results Show Significant Post

    07 May 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20190507005004/en/Mati-Therapeutics-Phase-II-Nepafenac-Evolute%C2%AE-Clinical/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==

    BUSINESSWIRE
    07 May 2019
    Share Share
    Mati Therapeutics PhII Results Signal Significant Post-op Pain Reduction
    Mati Therapeutics PhII Results Signal Significant Post-op Pain Reduction

    05 Sep 2018

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20180904005058/en/Mati-Therapeutics-Interim-Phase-II-Nepafenac-Clinical

    BUSINESSWIRE
    05 Sep 2018
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.